Current Updates on Protein As Biomarkers for Diabetic Kidney Disease: a Systematic Review

Overview

Journal Ther Adv Endocrinol Metab

Specialty Endocrinology

Date 2021 Nov 1

PMID 34721837

Citations 14

Authors

Rani Sauriasari

Dhonna Dwi Safitri

Nuriza Ulul Azmi

Affiliations

Soon will be listed here.

Abstract

Background: In the past decade, researchers have been focused on discovering protein biomarkers for diabetic kidney disease. This paper aims to search for, analyze, and synthesize current updates regarding the development of these efforts.

Methods: We systematically searched the ScienceDirect, SpringerLink, and PubMed databases for observational studies of protein biomarkers in patients with diabetes mellitus. We included studies published between January 2018 and April 2020, that were based on a population of patients with type-1 or type-2 diabetes mellitus aged ⩾18 years, with an observational design such as cross-sectional, case-control, or cohort studies. The dependent variable of the research results was in the form of protein biomarkers from urine, plasma, or serum.

Results: Following the screening process, 20 research articles with available full text met the inclusion criteria. These could be categorized as glomerular biomarkers (ANGPTL4, beta-2 microglobulin, Smad1, and glypican-5); inflammatory biomarkers (MCP-1 and adiponectin); and tubular biomarkers (NGAL, VDBP, megalin, sKlotho, and KIM-1). The development of a panel of biomarkers showed more promising results than those for a single biomarker in diagnosing diabetic kidney disease.

Conclusion: All the biomarkers discussed in this review showed promising results for predicting diabetic kidney disease because they correlate with albuminuria, eGFR, or both. However, of the 11 protein biomarkers, none have prognostic value beyond albuminuria and eGFR.

Citing Articles

A comprehensive review of biomarker research in diabetic nephropathy from a global bibliometric and visualization perspective.

Li Q, Xie Y, Zuo M, Li F Medicine (Baltimore). 2024; 103(48):e40729.

PMID: 39612398 PMC: 11608688. DOI: 10.1097/MD.0000000000040729.

CYSTATIN C-A Monitoring Perspective of Chronic Kidney Disease in Patients with Diabetes.

Visinescu A, Rusu E, Cosoreanu A, Radulian G Int J Mol Sci. 2024; 25(15).

PMID: 39125705 PMC: 11311327. DOI: 10.3390/ijms25158135.

Association between Albumin Alterations and Renal Function in Patients with Type 2 Diabetes Mellitus.

Nugnes M, Baldassarre M, Ribichini D, Tedesco D, Capelli I, Vetrano D Int J Mol Sci. 2024; 25(6).

PMID: 38542146 PMC: 10970212. DOI: 10.3390/ijms25063168.

Potential application of Klotho as a prognostic biomarker for patients with diabetic kidney disease: a meta-analysis of clinical studies.

Yu L, Sha M, Chen Y, Tan F, Liu X, Li S Ther Adv Chronic Dis. 2023; 14:20406223231213246.

PMID: 38058396 PMC: 10697044. DOI: 10.1177/20406223231213246.

Currently Used Methods to Evaluate the Efficacy of Therapeutic Drugs and Kidney Safety.

Huang H, Chou C, Sandar T, Liu W, Yang H, Lin Y Biomolecules. 2023; 13(11).

PMID: 38002263 PMC: 10669823. DOI: 10.3390/biom13111581.

References

Khan F, Fatima S, Khan G, Shahid S . Evaluation of kidney injury molecule-1 as a disease progression biomarker in diabetic nephropathy. Pak J Med Sci. 2019; 35(4):992-996. PMC: 6659046. DOI: 10.12669/pjms.35.4.154. View

Xiang A, Ekinci E, MacIsaac R . Inflammatory proteins in diabetic kidney disease-potential as biomarkers and therapeutic targets. Ann Transl Med. 2019; 7(Suppl 6):S243. PMC: 6789318. DOI: 10.21037/atm.2019.08.20. View

Pena M, Mischak H, Heerspink H . Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease. Diabetologia. 2016; 59(9):1819-31. PMC: 4969331. DOI: 10.1007/s00125-016-4001-9. View

Kim S, Jeong T, Lee W, Chun S, Sunwoo S, Kim S . Plasma Neutrophil Gelatinase-Associated Lipocalin as a Marker of Tubular Damage in Diabetic Nephropathy. Ann Lab Med. 2018; 38(6):524-529. PMC: 6056390. DOI: 10.3343/alm.2018.38.6.524. View

Abe H, Matsubara T, Iehara N, Nagai K, Takahashi T, Arai H . Type IV collagen is transcriptionally regulated by Smad1 under advanced glycation end product (AGE) stimulation. J Biol Chem. 2004; 279(14):14201-6. DOI: 10.1074/jbc.M310427200. View

Li L, Dong M, Wang X . The Implication and Significance of Beta 2 Microglobulin: A Conservative Multifunctional Regulator. Chin Med J (Engl). 2016; 129(4):448-55. PMC: 4800846. DOI: 10.4103/0366-6999.176084. View

Li R, Zhang L, Zhang S, Yang H, Yao B, Dong W . Levels and Clinical Significances of Glypican-5 in Urine of Type 2 Diabetic Nephropathy Cases. Iran J Kidney Dis. 2019; 13(3):173-181. View

Yamakado S, Cho H, Inada M, Morikawa M, Jiang Y, Saito K . Urinary adiponectin as a new diagnostic index for chronic kidney disease due to diabetic nephropathy. BMJ Open Diabetes Res Care. 2019; 7(1):e000661. PMC: 6557464. DOI: 10.1136/bmjdrc-2019-000661. View

Bjornstad P, Pyle L, Kinney G, Rewers M, Johnson R, Maahs D . Adiponectin is associated with early diabetic kidney disease in adults with type 1 diabetes: A Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. J Diabetes Complications. 2016; 31(2):369-374. PMC: 5156602. DOI: 10.1016/j.jdiacomp.2016.06.012. View

10.

Stanton R . Clinical challenges in diagnosis and management of diabetic kidney disease. Am J Kidney Dis. 2014; 63(2 Suppl 2):S3-21. DOI: 10.1053/j.ajkd.2013.10.050. View

11.

Bob F, Schiller A, Timar R, Lighezan D, Schiller O, Timar B . Rapid decline of kidney function in diabetic kidney disease is associated with high soluble Klotho levels. Nefrologia (Engl Ed). 2018; 39(3):250-257. DOI: 10.1016/j.nefro.2018.08.004. View

12.

Tian X, Zhao L, Ge J, Zhang Y, Xu Y . Elevated urinary level of vitamin D-binding protein as a novel biomarker for diabetic nephropathy. Exp Ther Med. 2014; 7(2):411-416. PMC: 3881051. DOI: 10.3892/etm.2013.1426. View

13.

Colhoun H, Marcovecchio M . Biomarkers of diabetic kidney disease. Diabetologia. 2018; 61(5):996-1011. PMC: 6448994. DOI: 10.1007/s00125-018-4567-5. View

14.

Ogasawara S, Hosojima M, Kaseda R, Kabasawa H, Yamamoto-Kabasawa K, Kurosawa H . Significance of urinary full-length and ectodomain forms of megalin in patients with type 2 diabetes. Diabetes Care. 2012; 35(5):1112-8. PMC: 3329833. DOI: 10.2337/dc11-1684. View

15.

Fawzy M, Abu AlSel B . Assessment of Vitamin D-Binding Protein and Early Prediction of Nephropathy in Type 2 Saudi Diabetic Patients. J Diabetes Res. 2018; 2018:8517929. PMC: 5903345. DOI: 10.1155/2018/8517929. View

16.

Nowak N, Skupien J, Smiles A, Yamanouchi M, Niewczas M, Galecki A . Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development. Kidney Int. 2018; 93(5):1198-1206. PMC: 5911430. DOI: 10.1016/j.kint.2017.11.024. View

17.

Pontillo C, Zhang Z, Schanstra J, Jacobs L, Zurbig P, Thijs L . Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker. Kidney Int Rep. 2017; 2(6):1066-1075. PMC: 5669285. DOI: 10.1016/j.ekir.2017.06.004. View

18.

Soni S, Cruz D, Bobek I, Chionh C, Nalesso F, Lentini P . NGAL: a biomarker of acute kidney injury and other systemic conditions. Int Urol Nephrol. 2009; 42(1):141-50. DOI: 10.1007/s11255-009-9608-z. View

19.

Said S, Nasr S . Silent diabetic nephropathy. Kidney Int. 2016; 90(1):24-6. DOI: 10.1016/j.kint.2016.02.042. View

20.

Bjornstad P, Cherney D, Maahs D . Update on Estimation of Kidney Function in Diabetic Kidney Disease. Curr Diab Rep. 2015; 15(9):57. PMC: 6429956. DOI: 10.1007/s11892-015-0633-2. View